Comparative Analysis of Peptides vs. AAS in Bodybuilding

How the two classes work

Anabolic-androgenic steroids (AAS) are testosterone and synthetic variants of it. They bind the androgen receptor in muscle and in nearly every other tissue, so the drug that drives muscle growth also acts on the skin and the brain, among other organs. The body reads high androgen levels as a signal to stop making its own testosterone, which is why natural production shuts down during a cycle.

The peptides lifters compare with AAS fall into two loose groups. Growth hormone secretagogues (ipamorelin, GHRP-2, GHRP-6, hexarelin) and growth-hormone-releasing hormone (GHRH) analogs (CJC-1295, sermorelin, tesamorelin) push the pituitary to release more of the body's own growth hormone, which raises IGF-1. Recovery peptides such as BPC-157 and TB-500 aren't hormone releasers; they're used for injuries on the strength of animal research. Neither group acts on the androgen receptor, and that difference explains most of the gap in results and side effects.

MK-677 (ibutamoren) also comes up constantly. It's an oral, non-peptide drug that works on the same ghrelin receptor as the GH secretagogues. For growth hormone itself and other non-steroid anabolics, see our comparison of peptides with growth hormone and insulin.

Muscle and strength: what the trials show

No trial has compared peptides with AAS head to head. Any comparison has to set separate studies side by side, and those studies differ in who took part and for how long, so treat the gap as a rough guide.

On the AAS side, the reference point is still a 1996 New England Journal of Medicine trial by Bhasin and colleagues in 43 healthy men. The men who trained while receiving 600 mg of testosterone enanthate a week for 10 weeks gained an average of 6.1 kg of fat-free mass. Their bench press rose 22 kg and their squat 38 kg, more than in either group that didn't train. That dose is far above a replacement dose, and the DEA says doses used outside medicine are often 10 to 100 times therapeutic ones.

For GH secretagogues, the longest controlled human trial tested MK-677. In a 2008 Annals of Internal Medicine trial, 65 healthy adults aged 60 to 81 took MK-677 or placebo daily for a year. Fat-free mass rose 1.1 kg on MK-677 and fell 0.5 kg on placebo. Strength didn't improve. We found no controlled trial of the injectable GH-releasing peptides that measured muscle growth in healthy young lifters.

That's about 6 kg of lean mass in 10 weeks against about 1 kg in a year, in very different populations. Unverified forum reports point the same way: lifters describe fast size and strength changes on AAS, while GH-peptide users more often mention sleep and recovery.

Fat loss

Forum guides often credit GH peptides with targeted loss of visceral fat. The MK-677 trial didn't find it: after a year, neither abdominal visceral fat nor total fat mass differed from placebo, and body weight rose 2.7 kg on MK-677 against 0.8 kg on placebo. AAS aren't fat-loss drugs either; users mainly describe them during a cut as a way to hold on to muscle. We didn't find a controlled trial that measured fat loss in dieting lifters on AAS.

Recovery and injury repair

Peptides are usually said to beat AAS here, yet this claim has the least human evidence. A 2025 systematic review of BPC-157 in orthopaedic sports medicine (HSS Journal) found 36 eligible studies, 35 of them preclinical. The one human study was a small retrospective series in which 7 of 12 people with chronic knee pain reported relief lasting more than six months after a knee injection. The review found no clinical safety data. As of October 2026, the human evidence for BPC-157 is three small uncontrolled pilots and no controlled trial with published results, which is why this site rates it as emerging evidence.

TB-500 has less. It's a seven-amino-acid fragment of thymosin beta-4, and as of October 2026 FDA says it has found no human exposure data for the fragment. Trials of the full protein don't carry over, so TB-500 sits at preliminary evidence: animal and cell data only.

Rodent studies of BPC-157 do consistently report faster healing of tendon and muscle injuries. Users report mixed results, with some describing clear improvement and many noticing nothing after several weeks. Product quality and the lack of any human healing trial both help explain that gap. AAS haven't been tested as injury-repair drugs in lifters either, so neither side has earned a "superior" rating for healing.

Side effects compared

The Endocrine Society's 2014 scientific statement on performance-enhancing drugs, mostly AAS, links their use to a higher risk of death and to disorders in nearly every organ system, from heart disease to psychiatric effects. It also notes that most users are non-athlete weightlifters. The DEA's list starts with testicular shrinkage and lower sperm count; it also notes raised cholesterol and liver damage with oral forms.

The peptide side has fewer documented harms, mostly because it has been studied so little. FDA says it lacks enough information on BPC-157 to know whether it would cause harm in people.

Both classes are mostly bought outside medical channels, so what's in the vial is its own risk. In the Paradigm Peptides case, prosecutors said government testing found real testosterone in all six products sold as SARMs, according to CBS News.

Using both

Users commonly describe running GH peptides or recovery peptides alongside an AAS cycle. No study has tested these combinations. The clearest interaction is blood sugar: reduced insulin sensitivity in the MK-677 trial adds a glucose question to the cholesterol and heart concerns that come with AAS. We found no study showing that any of these peptides speeds the return of natural testosterone after a cycle, a role some forum guides give them.

Legal and sport status

As of October 2026, anabolic steroids are Schedule III controlled substances under US federal law, according to the DEA's controlled substances list. Testosterone itself is also a prescription medicine.

The peptides in this comparison aren't controlled substances, but that doesn't make them legal drugs. None of the vials sold as "research use only" is an approved medicine. FDA's warning letters of March 31 and August 24, 2026 said RUO labels don't protect sellers whose sites make drug claims or sell bacteriostatic water for reconstitution, and FDA treated those products as unapproved new drugs. On July 30, 2026, a federal judge sentenced Paradigm Peptides owner Matthew Kawa to 70 months in prison after he pleaded guilty to selling unapproved drugs and illegal importation; BPC-157 was among the products charged, CBS News reported.

In April 2026 FDA moved BPC-157 and TB-500 out of Category 2, and in July 2026 an FDA advisory committee voted, against staff advice, to add them to the 503A compounding list. As of October 2026 FDA hasn't proposed a rule, so neither can be lawfully compounded under 503A.

For tested athletes there's no gap. WADA's 2026 Prohibited List, in force now, bans AAS under S1 and names BPC-157 under S0 (non-approved substances). TB-500 is named under S2.3, and GHRH analogs and GH secretagogues, MK-677 included, sit under S2.2.4. All are banned at all times. Our page on peptides and the Prohibited List for tested athletes covers testing in more detail.

Monitoring differences

The lab work follows the side effects. For AAS the markers are broad, from cholesterol and liver enzymes to testosterone and sperm count. For GH secretagogues the focus is fasting glucose and IGF-1, both tracked in the MK-677 trial. BPC-157 and TB-500 have no established blood marker, so there's nothing specific to measure for the drug itself. Our guide to monitoring protocols covers schedules and markers.

How the trade-offs differ

AAS have the larger and better-measured effect on muscle, and their harms are better measured too. Peptides show smaller measured effects on muscle, and much of their reputation for recovery rests on rodent studies and user reports. Their cleaner safety record partly reflects how little anyone has looked.

What we still don't know

Nobody has run a trial comparing a peptide with an AAS. Whether BPC-157 helps human tendon repair is untested; a University of Arkansas Phase 1 trial after rotator cuff surgery (NCT07803250, about 30 people) is listed as not yet recruiting, with a planned start of January 2027. Long-term safety of GH secretagogues at the doses young lifters use hasn't been studied, and FDA's next step on compounding BPC-157 and TB-500 is still open.